-
Challenges of combining cytotoxic chemotherapy and tyrosine kinase inhibitors
Michael P Chu, Vijaya L Damaraju & Michael B Sawyer
Perspective: Clinical Investigation
-
Challenges of combining cytotoxic chemotherapy and tyrosine kinase inhibitors
Michael P Chu, Vijaya L Damaraju & Michael B Sawyer
Perspective: Clinical Investigation
-
Challenges of combining cytotoxic chemotherapy and tyrosine kinase inhibitors
Michael P Chu, Vijaya L Damaraju & Michael B Sawyer
Perspective: Clinical Investigation
-
Challenges of combining cytotoxic chemotherapy and tyrosine kinase inhibitors
Michael P Chu, Vijaya L Damaraju & Michael B Sawyer
Perspective: Clinical Investigation
-
Challenges of combining cytotoxic chemotherapy and tyrosine kinase inhibitors
Michael P Chu, Vijaya L Damaraju & Michael B Sawyer
Perspective: Clinical Investigation
-
Challenges of combining cytotoxic chemotherapy and tyrosine kinase inhibitors
Michael P Chu, Vijaya L Damaraju & Michael B Sawyer
Perspective: Clinical Investigation
-
Challenges of combining cytotoxic chemotherapy and tyrosine kinase inhibitors
Michael P Chu, Vijaya L Damaraju & Michael B Sawyer
Perspective: Clinical Investigation
-
Challenges of combining cytotoxic chemotherapy and tyrosine kinase inhibitors
Michael P Chu, Vijaya L Damaraju & Michael B Sawyer
Perspective: Clinical Investigation
-
Implementation of strategic management tools improves wound care clinical trial outcomes
Marina Malikova, Lauren Shifflett & Alik Farber
Review: Clinical Trail Outcomes: Clinical Investigation
-
Implementation of strategic management tools improves wound care clinical trial outcomes
Marina Malikova, Lauren Shifflett & Alik Farber
Review: Clinical Trail Outcomes: Clinical Investigation
-
Implementation of strategic management tools improves wound care clinical trial outcomes
Marina Malikova, Lauren Shifflett & Alik Farber
Review: Clinical Trail Outcomes: Clinical Investigation
-
Implementation of strategic management tools improves wound care clinical trial outcomes
Marina Malikova, Lauren Shifflett & Alik Farber
Review: Clinical Trail Outcomes: Clinical Investigation
-
Implementation of strategic management tools improves wound care clinical trial outcomes
Marina Malikova, Lauren Shifflett & Alik Farber
Review: Clinical Trail Outcomes: Clinical Investigation
-
Implementation of strategic management tools improves wound care clinical trial outcomes
Marina Malikova, Lauren Shifflett & Alik Farber
Review: Clinical Trail Outcomes: Clinical Investigation
-
Implementation of strategic management tools improves wound care clinical trial outcomes
Marina Malikova, Lauren Shifflett & Alik Farber
Review: Clinical Trail Outcomes: Clinical Investigation
-
Implementation of strategic management tools improves wound care clinical trial outcomes
Marina Malikova, Lauren Shifflett & Alik Farber
Review: Clinical Trail Outcomes: Clinical Investigation
-
Adaptive Clinical Trials
Zoran Antonijevic
Foreword: Clinical Investigation
-
Adaptive Clinical Trials
Zoran Antonijevic
Foreword: Clinical Investigation
-
Adaptive Clinical Trials
Zoran Antonijevic
Foreword: Clinical Investigation
-
Adaptive Clinical Trials
Zoran Antonijevic
Foreword: Clinical Investigation
-
Adaptive Clinical Trials
Zoran Antonijevic
Foreword: Clinical Investigation
-
Adaptive Clinical Trials
Zoran Antonijevic
Foreword: Clinical Investigation
-
Adaptive Clinical Trials
Zoran Antonijevic
Foreword: Clinical Investigation
-
Adaptive Clinical Trials
Zoran Antonijevic
Foreword: Clinical Investigation
-
The need for even further progress with clinical trial data sharing efforts: patients are waiting
Sandra Morris, Karla G Childers, Jesse A Berlin, Joanne Waldstreicher
Editorial: Clinical Investigation
-
The need for even further progress with clinical trial data sharing efforts: patients are waiting
Sandra Morris, Karla G Childers, Jesse A Berlin, Joanne Waldstreicher
Editorial: Clinical Investigation
-
The need for even further progress with clinical trial data sharing efforts: patients are waiting
Sandra Morris, Karla G Childers, Jesse A Berlin, Joanne Waldstreicher
Editorial: Clinical Investigation
-
The need for even further progress with clinical trial data sharing efforts: patients are waiting
Sandra Morris, Karla G Childers, Jesse A Berlin, Joanne Waldstreicher
Editorial: Clinical Investigation
-
The need for even further progress with clinical trial data sharing efforts: patients are waiting
Sandra Morris, Karla G Childers, Jesse A Berlin, Joanne Waldstreicher
Editorial: Clinical Investigation
-
The need for even further progress with clinical trial data sharing efforts: patients are waiting
Sandra Morris, Karla G Childers, Jesse A Berlin, Joanne Waldstreicher
Editorial: Clinical Investigation
-
The need for even further progress with clinical trial data sharing efforts: patients are waiting
Sandra Morris, Karla G Childers, Jesse A Berlin, Joanne Waldstreicher
Editorial: Clinical Investigation
-
The need for even further progress with clinical trial data sharing efforts: patients are waiting
Sandra Morris, Karla G Childers, Jesse A Berlin, Joanne Waldstreicher
Editorial: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Treatment of heparin-induced thrombocytopenia: what are the contributions of clinical trials?
Moonjung Jung, Lawrence Rice
Review: Clinical Trail Outcomes: Clinical Investigation
-
Treatment of heparin-induced thrombocytopenia: what are the contributions of clinical trials?
Moonjung Jung, Lawrence Rice
Review: Clinical Trail Outcomes: Clinical Investigation
-
Treatment of heparin-induced thrombocytopenia: what are the contributions of clinical trials?
Moonjung Jung, Lawrence Rice
Review: Clinical Trail Outcomes: Clinical Investigation
-
Treatment of heparin-induced thrombocytopenia: what are the contributions of clinical trials?
Moonjung Jung, Lawrence Rice
Review: Clinical Trail Outcomes: Clinical Investigation
-
Treatment of heparin-induced thrombocytopenia: what are the contributions of clinical trials?
Moonjung Jung, Lawrence Rice
Review: Clinical Trail Outcomes: Clinical Investigation
-
Treatment of heparin-induced thrombocytopenia: what are the contributions of clinical trials?
Moonjung Jung, Lawrence Rice
Review: Clinical Trail Outcomes: Clinical Investigation
-
Treatment of heparin-induced thrombocytopenia: what are the contributions of clinical trials?
Moonjung Jung, Lawrence Rice
Review: Clinical Trail Outcomes: Clinical Investigation
-
Treatment of heparin-induced thrombocytopenia: what are the contributions of clinical trials?
Moonjung Jung, Lawrence Rice
Review: Clinical Trail Outcomes: Clinical Investigation
-
Fesoterodine fumarate for the treatment of overactive bladder in the elderly- a review of the latest clinical data
Adrian Wagg
Review: Clinical Trail Outcomes: Clinical Investigation
-
Fesoterodine fumarate for the treatment of overactive bladder in the elderly- a review of the latest clinical data
Adrian Wagg
Review: Clinical Trail Outcomes: Clinical Investigation
-
Fesoterodine fumarate for the treatment of overactive bladder in the elderly- a review of the latest clinical data
Adrian Wagg
Review: Clinical Trail Outcomes: Clinical Investigation
-
Fesoterodine fumarate for the treatment of overactive bladder in the elderly- a review of the latest clinical data
Adrian Wagg
Review: Clinical Trail Outcomes: Clinical Investigation
-
Fesoterodine fumarate for the treatment of overactive bladder in the elderly- a review of the latest clinical data
Adrian Wagg
Review: Clinical Trail Outcomes: Clinical Investigation
-
Fesoterodine fumarate for the treatment of overactive bladder in the elderly- a review of the latest clinical data
Adrian Wagg
Review: Clinical Trail Outcomes: Clinical Investigation
-
Fesoterodine fumarate for the treatment of overactive bladder in the elderly- a review of the latest clinical data
Adrian Wagg
Review: Clinical Trail Outcomes: Clinical Investigation
-
Fesoterodine fumarate for the treatment of overactive bladder in the elderly- a review of the latest clinical data
Adrian Wagg
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical trials and overactive bladder: lessons learned
Ariana L Smith, Alan J Wein
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical trials and overactive bladder: lessons learned
Ariana L Smith, Alan J Wein
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical trials and overactive bladder: lessons learned
Ariana L Smith, Alan J Wein
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical trials and overactive bladder: lessons learned
Ariana L Smith, Alan J Wein
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical trials and overactive bladder: lessons learned
Ariana L Smith, Alan J Wein
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical trials and overactive bladder: lessons learned
Ariana L Smith, Alan J Wein
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical trials and overactive bladder: lessons learned
Ariana L Smith, Alan J Wein
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical trials and overactive bladder: lessons learned
Ariana L Smith, Alan J Wein
Review: Clinical Trail Outcomes: Clinical Investigation
-
Immunosuppression and renal transplant rejection: review of current and emerging therapies
Roberto Marcen
Review Article: Clinical Investigation
-
Immunosuppression and renal transplant rejection: review of current and emerging therapies
Roberto Marcen
Review Article: Clinical Investigation
-
Immunosuppression and renal transplant rejection: review of current and emerging therapies
Roberto Marcen
Review Article: Clinical Investigation
-
Immunosuppression and renal transplant rejection: review of current and emerging therapies
Roberto Marcen
Review Article: Clinical Investigation
-
Immunosuppression and renal transplant rejection: review of current and emerging therapies
Roberto Marcen
Review Article: Clinical Investigation
-
Immunosuppression and renal transplant rejection: review of current and emerging therapies
Roberto Marcen
Review Article: Clinical Investigation
-
Immunosuppression and renal transplant rejection: review of current and emerging therapies
Roberto Marcen
Review Article: Clinical Investigation
-
Immunosuppression and renal transplant rejection: review of current and emerging therapies
Roberto Marcen
Review Article: Clinical Investigation
-
New considerations in the design of clinical trials for anti-atherosclerotic drugs
Therese M Heinonen, Donald M Black
Review Article: Clinical Investigation
-
New considerations in the design of clinical trials for anti-atherosclerotic drugs
Therese M Heinonen, Donald M Black
Review Article: Clinical Investigation
-
New considerations in the design of clinical trials for anti-atherosclerotic drugs
Therese M Heinonen, Donald M Black
Review Article: Clinical Investigation
-
New considerations in the design of clinical trials for anti-atherosclerotic drugs
Therese M Heinonen, Donald M Black
Review Article: Clinical Investigation
-
New considerations in the design of clinical trials for anti-atherosclerotic drugs
Therese M Heinonen, Donald M Black
Review Article: Clinical Investigation
-
New considerations in the design of clinical trials for anti-atherosclerotic drugs
Therese M Heinonen, Donald M Black
Review Article: Clinical Investigation
-
New considerations in the design of clinical trials for anti-atherosclerotic drugs
Therese M Heinonen, Donald M Black
Review Article: Clinical Investigation
-
New considerations in the design of clinical trials for anti-atherosclerotic drugs
Therese M Heinonen, Donald M Black
Review Article: Clinical Investigation